Cargando…

Model-based cost-effectiveness analyses comparing combinations of urate lowering therapy and anti-inflammatory treatment in gout patients

OBJECTIVES: To assess the cost-effectiveness of various combinations of urate lowering therapy (ULT) and anti-inflammatory treatment in the management of newly diagnosed gout patients, from the Dutch societal perspective. METHODS: A probabilistic patient-level simulation estimating costs and quality...

Descripción completa

Detalles Bibliográficos
Autores principales:	van de Laar, Celine Johanna, Janssen, Carly A., Janssen, Matthijs, Oude Voshaar, Martijn A. H., AL, Maiwenn J., van de Laar, Mart A. F. J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797232/ https://www.ncbi.nlm.nih.gov/pubmed/35089941 http://dx.doi.org/10.1371/journal.pone.0261940

Ejemplares similares

Quality of care in gout: a clinical audit on treating to the target with urate lowering therapy in real-world gout patients
por: Janssen, Carly A., et al.
Publicado: (2017)

A retrospective analysis of medication prescription records for determining the levels of compliance and persistence to urate-lowering therapy for the treatment of gout and hyperuricemia in The Netherlands
por: Janssen, C. A., et al.
Publicado: (2018)

Development and validation of a patient-reported gout attack intensity score for use in gout clinical studies
por: Janssen, Carly A, et al.
Publicado: (2019)

A systematic literature review of patient-reported outcome measures used in gout: an evaluation of their content and measurement properties
por: Janssen, Carly A., et al.
Publicado: (2019)

Cost-effectiveness of different treat-to-target strategies in rheumatoid arthritis: results from the DREAM registry
por: van de Laar, Celine J., et al.
Publicado: (2019)

Development of a patient decision aid for the initiation of urate-lowering therapy in gout patients
por: te Kampe, Ritch, et al.
Publicado: (2022)

Cost-Effectiveness of a JAK1/JAK2 Inhibitor vs a Biologic Disease-Modifying Antirheumatic Drug (bDMARD) in a Treat-to-Target Strategy for Rheumatoid Arthritis
por: Van De Laar, Celine J, et al.
Publicado: (2020)

Development and usability of a web-based patient-tailored tool to support adherence to urate-lowering therapy in gout
por: te Kampe, Ritch, et al.
Publicado: (2022)

Measurement properties of physical function scales validated for use in patients with rheumatoid arthritis: A systematic review of the literature
por: Oude Voshaar, Martijn AH, et al.
Publicado: (2011)

Adherence with urate-lowering therapies for the treatment of gout
por: Harrold, Leslie R, et al.
Publicado: (2009)

Measuring everyday functional competence using the Rasch assessment of everyday activity limitations (REAL) item bank
por: Oude Voshaar, Martijn A. H., et al.
Publicado: (2017)

Dutch translation and cross-cultural adaptation of the PROMIS(® )physical function item bank and cognitive pre-test in Dutch arthritis patients
por: Oude Voshaar, Martijn AH, et al.
Publicado: (2012)

Variation in serum urate levels in the absence of gout and urate lowering therapy
por: Shaffer, Andrew, et al.
Publicado: (2021)

Psychometric properties and cross-language equivalence of the revised Bristol Rheumatoid Arthritis Fatigue and the Rheumatoid Arthritis Impact of Disease scales in rheumatoid arthritis
por: Oude Voshaar, Martijn A. H., et al.
Publicado: (2019)

Urate‐lowering therapy for patients with gout on hemodialysis
por: Alkilany, Reem, et al.
Publicado: (2022)

Development and preliminary evaluation of a short self-report measure of generalized pain hypersensitivity
por: van Bemmel, Peter F, et al.
Publicado: (2019)

Cost Comparison of Urate-Lowering Therapies in Patients with Gout and Moderate-to-Severe Chronic Kidney Disease
por: Mitri, Ghaith, et al.
Publicado: (2016)

Pleiotropic effect of the ABCG2 gene in gout: involvement in serum urate levels and progression from hyperuricemia to gout
por: Wrigley, Rebekah, et al.
Publicado: (2020)

Effect of Fenofibrate in Combination with Urate Lowering Agents in Patients with Gout
por: Lee, You-Hyun, et al.
Publicado: (2006)

Treatment approaches and adherence to urate-lowering therapy for patients with gout
por: Aung, Thanda, et al.
Publicado: (2017)

Barriers and facilitators to disease-modifying antirheumatic drug use in patients with inflammatory rheumatic diseases: a qualitative theory-based study
por: Voshaar, Marieke, et al.
Publicado: (2016)

The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age
por: Jackson, Robert L, et al.
Publicado: (2012)

Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort
por: Singh, Jasvinder A, et al.
Publicado: (2015)

Urate in fingernail represents the deposition of urate burden in gout patients
por: Chen, Haibing, et al.
Publicado: (2020)

Urate-lowering treatment and risk of total joint replacement in patients with gout
por: Kuo, Chang-Fu, et al.
Publicado: (2018)

Urate-lowering Therapy and Chronic Kidney Disease Development in Patients with Gout
por: Yen, Fu-Shun, et al.
Publicado: (2021)

The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial
por: Becker, Michael A, et al.
Publicado: (2010)

Gout Remission as a Goal of Urate-Lowering Therapy: A Critical Review
por: Tabi-Amponsah, Adwoa Dansoa, et al.
Publicado: (2023)

Erratum to: Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort
por: Singh, Jasvinder A., et al.
Publicado: (2015)

Radiographic progression can still occur in individual patients with low or moderate disease activity in the current treat-to-target paradigm: real-world data from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry
por: ten Klooster, Peter M., et al.
Publicado: (2019)

Impact of diuretics on the urate lowering therapy in patients with gout: analysis of an inception cohort
por: Ranieri, Laura, et al.
Publicado: (2018)

High Rate of Adherence to Urate-Lowering Treatment in Patients with Gout: Who’s to Blame?
por: Perez-Ruiz, Fernando, et al.
Publicado: (2020)

Systemic Urate Deposition: An Unrecognized Complication of Gout?
por: Khanna, Puja, et al.
Publicado: (2020)

The Effect of Decrease in Serum Urate for the Risk of Gout Flares During Urate-Lowering Therapy Initiation Among Chinese Male Gout Patients: A Prospective Cohort Study
por: Pang, Lei, et al.
Publicado: (2023)

Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout
por: Dalbeth, Nicola, et al.
Publicado: (2012)

Facilitators and barriers to adherence to urate-lowering therapy in African-Americans with gout: a qualitative study
por: Singh, Jasvinder A
Publicado: (2014)

Two parallel short forms to measure disease- and treatment-associated knowledge in rheumatoid arthritis: application of item response theory
por: Spijk-de Jonge, Marieke J, et al.
Publicado: (2020)

Coevolution of URAT1 and Uricase during Primate Evolution: Implications for Serum Urate Homeostasis and Gout
por: Tan, Philip K., et al.
Publicado: (2016)

Assessing the sensitivity to change of the OMERACT ultrasound structural gout lesions during urate-lowering therapy
por: Christiansen, Sara Nysom, et al.
Publicado: (2020)

Urate-lowering therapy may mitigate the risks of hospitalized stroke and mortality in patients with gout
por: Yen, Fu-Shun, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7m2r254jnktr1ag01ckspnhogu